Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) CFO David Thomas Evans acquired 50,000 shares of Cardlytics stock in a transaction on Monday, May 18th. The shares were bought at an average cost of $0.63 per share, for a total transaction of $31,500.00. Following the completion of the transaction, the chief financial officer owned 317,930 shares in the company, valued at approximately $200,295.90. This trade represents a 18.66% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
David Thomas Evans also recently made the following trade(s):
- On Friday, May 15th, David Thomas Evans acquired 150,000 shares of Cardlytics stock. The shares were bought at an average cost of $0.65 per share, for a total transaction of $97,500.00.
Cardlytics Trading Up 21.7%
Shares of Cardlytics stock opened at $0.73 on Thursday. The company’s fifty day simple moving average is $0.87 and its two-hundred day simple moving average is $1.04. The company has a market cap of $41.77 million, a P/E ratio of -0.41 and a beta of 0.67. Cardlytics, Inc. has a 12-month low of $0.57 and a 12-month high of $3.28.
Institutional Trading of Cardlytics
Hedge funds and other institutional investors have recently modified their holdings of the business. Quinn Opportunity Partners LLC grew its position in shares of Cardlytics by 900.0% in the 3rd quarter. Quinn Opportunity Partners LLC now owns 1,100,000 shares of the company’s stock worth $2,673,000 after buying an additional 990,000 shares during the period. Vanguard Personalized Indexing Management LLC purchased a new stake in Cardlytics during the 3rd quarter valued at about $26,000. Thompson Davis & CO. Inc. purchased a new stake in Cardlytics during the 3rd quarter valued at about $111,000. Renaissance Technologies LLC purchased a new stake in Cardlytics during the 4th quarter valued at about $62,000. Finally, Goldman Sachs Group Inc. grew its position in Cardlytics by 15.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 109,001 shares of the company’s stock valued at $125,000 after purchasing an additional 14,273 shares during the last quarter. 68.10% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the stock. Lake Street Capital set a $1.00 price objective on shares of Cardlytics in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cardlytics in a research report on Friday, April 10th. Evercore set a $1.00 price objective on shares of Cardlytics in a research report on Friday, March 6th. Bank of America reaffirmed an “underperform” rating on shares of Cardlytics in a research report on Thursday, March 5th. Finally, Wall Street Zen raised shares of Cardlytics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. One research analyst has rated the stock with a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Cardlytics presently has a consensus rating of “Sell” and a consensus target price of $1.00.
Read Our Latest Research Report on CDLX
Cardlytics Company Profile
Cardlytics, Inc operates a purchase intelligence and marketing platform that connects advertisers with consumers through bank and credit card transaction data. The company partners with financial institutions to analyze anonymized purchase information, enabling brands to deliver highly targeted offers and rewards directly to customers’ online and mobile banking channels. By leveraging real-time insights into consumer spending habits, Cardlytics helps marketers optimize campaign performance and measure return on ad spend more accurately than traditional digital advertising methods.
At the core of Cardlytics’ offering is its proprietary purchase intelligence engine, which aggregates and anonymizes transaction data from partner banks and credit unions.
Read More
- Five stocks we like better than Cardlytics
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.
